All In Biotech

Drug Trial Radar · NCT06456346

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jul 16, 2024

Primary completion

Sep 28, 2027

Study completion Mar 24, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.

Conditions

  • Essential Thrombocythemia

Interventions

  • BomedemstatDrug

    Oral capsule

  • HydroxyureaDrug

    Oral capsule

  • Bomedemstat placeboDrug

    Oral capsule placebo

  • Hydroxyurea placeboDrug

    Oral capsule placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Durable Clinicohematologic Response (DCHR) RateTime frame: Up to approximately 52 weeks

Locations

171 sites in 23 countries. Site status is shown where the registry gives one.

  • Palo Verde Cancer Specialists ( Site 0052)

    Glendale, Arizona

  • Los Angeles Cancer Network ( Site 0025)

    Glendale, California

  • Stanford Cancer Center ( Site 0024)

    Palo Alto, California

  • Exempla Lutheran Medical Center ( Site 0014)

    Golden, Colorado

  • Yale University School of Medicine ( Site 0051)

    New Haven, Connecticut

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0006)

    Fort Wayne, Indiana

  • University of Michigan ( Site 0003)

    Ann Arbor, Michigan

  • Optum Care Cancer Center ( Site 0053)

    Las Vegas, Nevada

  • Levine Cancer Institute ( Site 0009)

    Charlotte, North Carolina

  • Duke University Health System (DUHS) ( Site 0012)

    Durham, North Carolina

  • Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013)

    Winston-Salem, North Carolina

  • The Ohio State University Wexner Medical Center ( Site 0028)

    Columbus, Ohio

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8005)

    Eugene, Oregon

  • Oregon Health & Science University ( Site 0018)

    Portland, Oregon

  • TriStar Bone Marrow ( Site 7000)

    Nashville, Tennessee

  • Texas Oncology - West Texas ( Site 8003)

    Amarillo, Texas

  • Texas Oncology - DFW ( Site 8006)

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center ( Site 0026)

    Houston, Texas

  • University of Texas Health Science Center at San Antonio ( Site 0021)

    San Antonio, Texas

  • Texas Oncology - Gulf Coast ( Site 8008)

    Webster, Texas

  • University of Virginia ( Site 0020)

    Charlottesville, Virginia

  • VCU Health Adult Outpatient Pavillion ( Site 0008)

    Richmond, Virginia

  • Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0105)

    Santa Fe, Argentina

  • Hospital Universitario Austral ( Site 0101)

    Pilar, Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires ( Site 0102)

    ABB, Buenos Aires F.D., Argentina

  • C.I.C.E. 9 de Julio ( Site 0104)

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Westmead Hospital ( Site 0201)

    Westmead, New South Wales, Australia

  • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0203)

    Adelaide, South Australia, Australia

  • Monash Health-Haematology Research ( Site 0202)

    Clayton, Victoria, Australia

  • Austin Health-Cancer Clinical Trials Centre ( Site 0206)

    Heidelberg, Victoria, Australia

  • Royal Perth Hospital-Haematology ( Site 0204)

    Perth, Western Australia, Australia

  • Ordensklinikum Linz GmbH Elisabethinen ( Site 0562)

    Linz, Upper Austria, Austria

  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0038)

    Calgary, Alberta, Canada

  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0037)

    Greenfield Park, Quebec, Canada

  • Biocenter ( Site 0149)

    Concepción, Biobio, Chile

  • IC La Serena Research ( Site 0150)

    La Serena, Coquimbo Region, Chile

  • FALP-UIDO ( Site 0148)

    Santiago, Region M. de Santiago, Chile

  • Clínica Inmunocel ( Site 0147)

    Santiago, Region M. de Santiago, Chile

  • Clínica Alemana de Santiago ( Site 0143)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 0142)

    Santiago, Region M. de Santiago, Chile

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.